FY2024 EPS Estimates for Stereotaxis Decreased by Analyst

Stereotaxis, Inc. (NYSEAMERICAN:STXS) – Equities research analysts at Roth Capital reduced their FY2024 earnings per share estimates for Stereotaxis in a report issued on Tuesday, November 12th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.24) per share for the year, down from their prior estimate of ($0.22). The consensus estimate for Stereotaxis’ current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Stereotaxis’ Q4 2024 earnings at ($0.04) EPS, Q1 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.17) EPS.

Stereotaxis (NYSEAMERICAN:STXS) last released its quarterly earnings results on Monday, November 11th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 153.10%. The business had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $6.80 million.

Stereotaxis Stock Performance

NYSEAMERICAN STXS opened at $2.04 on Friday. The stock has a market cap of $172.71 million, a P/E ratio of -7.29 and a beta of 1.55. Stereotaxis has a 52-week low of $1.47 and a 52-week high of $3.29.

Hedge Funds Weigh In On Stereotaxis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC increased its position in Stereotaxis by 56.0% during the 1st quarter. Virtu Financial LLC now owns 32,690 shares of the company’s stock worth $85,000 after purchasing an additional 11,739 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Stereotaxis during the first quarter worth $58,000. Bank of New York Mellon Corp boosted its holdings in shares of Stereotaxis by 247.5% during the second quarter. Bank of New York Mellon Corp now owns 189,592 shares of the company’s stock worth $345,000 after purchasing an additional 135,041 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Stereotaxis by 7.7% in the first quarter. Vanguard Group Inc. now owns 2,613,966 shares of the company’s stock valued at $6,822,000 after purchasing an additional 187,437 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Stereotaxis by 46.2% in the second quarter. Renaissance Technologies LLC now owns 488,700 shares of the company’s stock valued at $889,000 after purchasing an additional 154,400 shares during the last quarter. 45.35% of the stock is currently owned by hedge funds and other institutional investors.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.